hindi.revoi.in
  • होम
  • राष्ट्रीय
  • अंतरराष्ट्रीय
  • कारोबार
  • राज्य
    • दिल्ली
    • उत्तरप्रदेश
    • महाराष्ट्र
    • मध्यप्रदेश
    • राजस्थान
  • राजनीति
  • खेल
Reading: Good News: “Covaxin” Showed Minimum Adverse Impact and Robust Immune Response
Share
  • ગુજરાતી
  • English
Font ResizerAa
hindi.revoi.inhindi.revoi.in
  • होम
  • राष्ट्रीय
  • अंतरराष्ट्रीय
  • कारोबार
  • राज्य
  • राजनीति
  • खेल
Search
  • होम
  • राष्ट्रीय
  • अंतरराष्ट्रीय
  • कारोबार
  • राज्य
    • दिल्ली
    • उत्तरप्रदेश
    • महाराष्ट्र
    • मध्यप्रदेश
    • राजस्थान
  • राजनीति
  • खेल
Follow US
hindi.revoi.in > Blog > revoinews > Good News: “Covaxin” Showed Minimum Adverse Impact and Robust Immune Response
revoinews

Good News: “Covaxin” Showed Minimum Adverse Impact and Robust Immune Response

Editor In Chief
Last updated: December 16, 2020 9:34 pm
Editor In Chief
Published: December 16, 2020
Share
SHARE

NEW DELHI, Dec 16: Very good news for India. “Covaxin” has produced “robust immune response” against the Corona disease and showed that “majority of the adverse events” were mild and got resolved soon.

Covaxin is the indigenous Corona vaccine being developed by Hyderabad-based Bharat Biotech. Though it is too early to rejoice because the vaccine is only going through the phase I trial but the results showed so far was encouraging.

The company on Wednesday released the results of the Phase 1 trials of its ‘Covaxin’ which “produced a robust immune response against the disease and showed that the majority of the adverse events were mild and got resolved.” Another good news was that the “vaccine is being stored between 2-8 degrees Celsius and further efficacy trials are underway.” The other world leader in the section, Pfizer vaccine, required to be stored in minus 70 degrees Celsius.

The results of the first phase of Covaxin- which Bharat Biotech is developing in collaboration with the Indian Council of Medical Research (ICMR) comes a day after the Drugs Controller General of India (DGCI) had said it was examining the application submitted by the company seeking emergency use authorisation of its vaccine.

Emergency approval for any vaccine or drug can only be granted once the regulatory body carries out an assessment of its safety and effectiveness, based on the data obtained from the efficacy trials.

Earlier, Bharat Biotech was told by the Subject Expert Committee (SEC) on emergency use authorization of vaccines that it needs to submit more data on Covaxin before it can be granted approval.

Meanwhile, India along with the United Kingdom launched a virtual vaccines hub which will share best practice for clinical trials and foster innovation besides helping in the shared fight against Covid-19 pandemic. British Foreign Secretary Dominic Raab currently visiting India announced that experts from the two countries would join forces through a new virtual hub to deliver vaccines for coronavirus and other deadly viruses.

India on Wednesday had registered 26,382 new Covid-19 cases and 387-related fatalities which pushed the overall tally to over 9.9 million. The active cases stand at 332,002 and are declining steadily while 9.45 million people have recovered from the disease till now, the union health ministry release on Wednesday said.

(Manas Dasgupta)

 

You Might Also Like

શિયાળાની ઋતુમાં તમારા નાસ્તામાં બનાવો ગરમા-ગરમ સ્પાઈસી ‘ગ્રીન ચીલી પોટેટો’
ગઠબંધન પર મંથન: શરદ પવારે કર્યો ફોન પણ જગન મોહન રેડ્ડીએ ન કરી વાત
કોરોનાની ગતિ પડી ધીમી – 4 મહિના બાદ છેલ્લા 24 કલાકમાં નોંધાયા આટલા ઓછા કેસ
પાકિસ્તાનને ભારતથી કોઈ ખતરો નથીઃ ISIના પૂર્વ પ્રમુખ
Government of India to show green signal to 45 Chinese investments: Report
Share This Article
Facebook Email Print
Popular News
राजनीतिराष्ट्रीयहिन्दी

जेपीएससी-JSSC भर्ती विवाद: राहुल गांधी ने छात्रों से फोन पर की बातचीत, कहा- व्हाट्सएप पर भेजें मांगों का ज्ञापन

August 7, 2026

सलमान खान के घर के बाहर ड्यूटी पर तैनात पुलिसकर्मी की मौत, हार्ट अटैक की आशंका

Aban Ahmed : प्रयागराज पहुंचा अबान का शव, अतीक-अशरफ और असद की कब्र के पास होगा सुपुर्द-ए-खाक

भारतीय नाविकों की सुरक्षा सर्वोच्च प्राथमिकता, खाड़ी क्षेत्र में 24 घंटे हेल्पलाइन सक्रिय : विदेश मंत्रालय

Share Market Today: गिरावट के साथ खुला शेयर बाजार, सेंसेक्स 267 अंक टूटा, निफ्टी 24,600 के नीचे

JPSC-JSSC Protest: 14वें दिन भी जारी छात्रों का आंदोलन, भूख हड़ताल पर अड़े अभ्यर्थी; पेपर लीक जांच की मांग तेज

National Handloom Day 2026: पीएम मोदी बोले- हथकरघा क्षेत्र आत्मनिर्भर भारत और महिला सशक्तिकरण का मजबूत आधार

राघव चड्ढा ने पीएम मोदी से की मुलाकात, बोले- एक सुबह जो हमेशा याद रहेगी

Chamba Bus Accident : चंबा में दर्दनाक बस हादसा, ड्राइवर-कंडक्टर समेत 7 की मौत; 11 घायल

NSF कॉन्क्लेव में बोले खेल मंत्री मांडविया- ‘चयन प्रक्रिया निष्पक्ष हो, किसी एथलीट के साथ नाइंसाफी नहीं होनी चाहिए’

Ad imageAd image

लोकप्रिय श्रेणियां

  • राष्ट्रीय
  • राजनीति
  • अंतरराष्ट्रीय
  • खेल
  • राज्य
  • चुनाव
  • कारोबार
  • देश-विदेश
  • बॉलीवुड
  • मनोरंजन
  • व्यापार

About US

REVOI is a independent media start-up. We are a new-age media company with a rich and storied legacy. REVOI believes : “INFACT EVERY PERSON ON THIS EARTH IS ARGUABLY A STAKEHOLDER IN EVERY ORGANISATION ON THIS PLANET”
Quick Link
  • ગુજરાતી
  • English
Top Categories

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

    © 2026 Trim Media Private Limited. All Rights Reserved.
    Welcome Back!

    Sign in to your account

    Username or Email Address
    Password

    Lost your password?